

## **Fulcrum Therapeutics to Report Third Quarter 2019 Financial Results on Thursday, November 14, 2019**

November 6, 2019 at 8:01 AM EST

CAMBRIDGE, Mass., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, November 14, 2019 to report its third quarter 2019 financial results and provide a corporate update.

The live call may be accessed by dialing (800) 527-6973 for domestic callers or (470) 495-9162 for international callers and providing the conference ID number 1688051. An audio webcast of the call will be available on the Company's website at <https://ir.fulcrumtx.com/events-and-presentations>. Following the live webcast, an archived replay will also be available.

### **About Fulcrum Therapeutics**

Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum's proprietary product engine identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression. Please visit [www.fulcrumtx.com](http://www.fulcrumtx.com).

### **Investor Contact:**

Christina Tartaglia  
Stern Investor Relations, Inc.  
212.362.1200  
[christina@sternir.com](mailto:christina@sternir.com)

### **Media Contact:**

Kaitlin Gallagher  
Berry & Company Public Relations  
[kgallagher@berrypr.com](mailto:kgallagher@berrypr.com)  
212-253-8881